Seeking Alpha

CytRx gives aldoxorubicin update, shares rise

  • CytRx (CYTR) is out with some interim data from a Phase 2b trial of aldoxorubicin versus doxorubicin as a first-line treatment for advanced soft tissue sarcomas.
  • ORR for the aldoxorubicin group was 22% versus 0% for the doxorubicin group and CYTR says only 32% of patients that received aldoxorubicin experienced progressive disease versus 50% of patients who received doxorubicin.
  • SAEs: 24 for aldoxorubicin versus 6 for doxorubicin (ultimately, none of the SAEs required discontinuation of treatment).
  • Top-line PFS data is expected in December. (PR)
  • CYTR +2% premarket
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector